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lopidogrel Inhibits Platelet-Leukocyte
nteractions and Thrombin Receptor
gonist Peptide-Induced Platelet Activation
n Patients With an Acute Coronary Syndrome
ihui Xiao, PHD, Pierre The´roux, MD
ontreal, Quebec, Canada
OBJECTIVES We sought to characterize the effects of clopidogrel on the activation of circulating platelets,
the activation and aggregation of ex vivo platelets, and the interactions with leukocytes in
patients with a non–ST-segment elevation in acute coronary syndromes (ACS).
BACKGROUND The significant benefits of clopidogrel in cardiovascular trials suggest that blockage of the
P2Y12 receptor may be associated with important biologic consequences.
METHODS Blood samples obtained from 23 ACS patients before and 24 h after a loading dose of
clopidogrel (300 mg) were analyzed by whole-blood flow cytometry, light transmission
aggregometry in platelet-rich plasma, and plasma enzyme-linked immunoassays. A thrombin
receptor agonist peptide (TRAP) and adenosine diphosphate (ADP) were used as agonists.
Normal individuals pretreated with aspirin served as controls.
RESULTS Clopidogrel attenuated platelet aggregation to both ADP (10 mol/l) and TRAP (10
mol/l) by 22% and P-selectin expression by 16% and 25%, respectively. The drug decreased
the excess platelet-monocyte and platelet-neutrophil conjugates found in the blood of ACS
patients (p  0.01) and prevented their formation ex vivo with agonist stimulation. Plasma
levels of soluble CD40L were reduced by 27% (p  0.001) and of soluble P-selectin by 15%
(p  0.001).
CONCLUSIONS Clopidogrel attenuates the agonist effects of ADP and TRAP on platelet secretion,
aggregation, and formation of platelet-monocyte and platelet-neutrophil conjugates in
patients with ACS. These effects may all contribute to the clinical benefits of the drug in these
syndromes. (J Am Coll Cardiol 2004;43:1982–8) © 2004 by the American College of
Cardiology Foundationc
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rlopidogrel is a thienopyridine that specifically acts on the
latelet P2Y12 purinergic receptor (1). Clinical trials have
onsistently shown that the drug prevents acute ischemic
vents (2–5), although it only partially blocks the adenosine
iphosphate (ADP) receptor, with a high degree of inter-
ndividual variability (6,7). As indirect effects of the drug
ould contribute to the benefits, this study looks at mech-
nisms other than the inhibition of ADP-induced platelet
ggregation that could be useful in patients with a non–
T-segment elevation acute coronary syndrome (ACS).
See page 1989
he interactions between different pathways to platelet
ctivation are indeed numerous, and the inhibition of one
athway may influence others. Similarly, numerous cross-
inks exist between thrombosis and inflammation in ACS;
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ontreal, Montreal, Quebec, Canada. This study was supported by internal research
unding from Montreal Heart Institute.
Manuscript received July 7, 2003; revised manuscript received October 15, 2003,iccepted October 20, 2003.onsequently, antithrombotic drug therapy may influence
he inflammation process, and vice versa, amplifying or
egating the net gain derived from given therapies.
Circulating platelet-leukocyte conjugates are considered a
ensitive marker of the interactions that exist between
nflammation and thrombosis. The interactions elicit white
ell activation with upregulation of CD11b/CD18, cytokine
roduction, and expression of tissue factor and procoagulant
ctivity in monocytes (8–11). The conjugates are elevated in
nstable angina (12,13); acute myocardial infarction, where
hey precede the elevation of creatine kinase-MB isoenzyme
14); during cardiopulmonary bypass surgery (15); and
uring percutaneous coronary interventions (16). CD40L is
ecreted by platelets and lymphocytes and binds the recep-
ors present on numerous cells that are involved in the
rocesses of atherosclerosis, plaque inflammation, and
hrombosis (10,11,17).
Previous studies have suggested some anti-inflammatory
roperties of clopidogrel. A reduction in the number of
latelet-leukocyte interactions has been described (18,19),
nd one study reported a special benefit of the drug in
educing the augmented risk of percutaneous interventions
n patients with elevated levels of C-reactive protein (20).
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tudy population. Twenty-three patients (7 women and
6 men; 58  10 years of age) were studied within 24 h of
ospital admission for a non–ST-segment elevation ACS,
nd 20 normal individuals served as controls for the platelet-
eukocyte conjugate studies. An ACS was defined as chest
ain lasting 5 min or more at rest, with the presence of an
schemic ST-T segment or an increase in blood levels of
roponin T. At the time of the study, all patients had
eceived a 160-mg dose of aspirin and an intravenous bolus
f 60 U/kg of unfractionated heparin; they all received an
nfusion of heparin for at least 6 h at a rate of 12 U/kg/h,
itrated to an activated partial thromboplastin time of 1.5 to
.5 times the upper limit of normal. No other thromboac-
ive drugs, including glycoprotein (GP) IIb/IIIa antagonists,
ere used. Other cardiovascular drugs included beta-
lockers in 19 patients, nitrates in 13 patients, and calcium
ntagonists in 6 patients. Sixteen patients had previous
tatin therapy, and a statin was initiated at hospital admis-
ion in two other patients. Control subjects received no
rugs, except for 160 mg aspirin administered for the
urpose of this study. The local ethics committee approved
he study, and all patients signed an informed consent form.
lood sampling. Blood samples were obtained from an
ntecubital vein using a 21-gauge butterfly needle. The
lood was collected in a plastic tube containing
-phenylalanyl-prolyl-arginine chloromethyl ketone (final
oncentration of 40 mol/l), after having discarded the first
ml of free running blood, and was processed within the
ollowing 10 to 15 min. Patients were studied before and
4 h after an oral loading dose of 300 mg clopidogrel.
ontrol subjects had a single blood sample while on aspirin.
latelet aggregation studies. Platelet aggregation was
easured in platelet-rich plasma (PRP) using light trans-
ission aggregometry (Model 570 VS, Chronolog Corp.,
avertown, Pennsylvania). The PRP was prepared by
entrifugation of the whole blood at 150g (850 rpm) for 10
in, and the platelet-poor plasma (PPP) by centrifugation
f the remaining blood at 2,200 g (3,500 rpm) for an
dditional 15 min. The PRP and PPP were used to set 0%
nd 100% light transmission, respectively. Platelet aggrega-
ion was measured for 10 min after the addition of ADP
final concentration of 10 mol/l) or thrombin receptor
Abbreviations and Acronyms
ACS  acute coronary syndrome
ADP  adenosine diphosphate
FITC  fluorescein isothiocyanate
Ig  immunoglobulin
PAR  protease-activated receptor
PMN  polymorphonuclear cell
PPP  platelet-poor plasma
PRP  platelet-rich plasma
TRAP  thrombin receptor agonist peptidegonist peptide (TRAP) (amino acid sequence: SFLLRN- aHDKYEPF; final concentration of 10 mol/l) and was
valuated as the percentage of light transmission at 10 min.
low cytometric assays. The monoclonal antibodies anti-
D14-PC5 (Immunotech, Marseille, France), anti-
D42a-FITC (Becton Dickinson, Mississauga, Ontario,
anada), anti-CD62P-PE (Becton Dickinson), and their
egative controls were used to label monocytes or neutro-
hils, platelets, and platelet membrane P-selectin,
espectively.
-selectin expression. Whole blood gently mixed with
PP at a ratio of 1:4 was added in an Eppendorff tube
ontaining a saturating concentration of anti-CD62P-PE
mouse immunoglobulin [Ig]G1), 10 mol/l ADP, or 10
mol/l TRAP (final concentrations), or an equal volume of
yrode’s buffer solution (pH 7.4). After a 30-min period of
ncubation in static conditions at 26°C, formaldehyde di-
uted in a Tyrode’s buffer solution (1.0% final concentration)
as added to stop the reaction. The fixed samples were
nalyzed within the following hour using a Coulter EPICS
L flow cytometer (Beckman-Coulter, Miami, Florida).
he instrument computer system was used to quantify
uorescein isothiocyanate (FITC) fluorescence-positive
latelets as the percentage of the total number of platelets.
latelet-leukocyte aggregates. Whole blood was mixed
ently in an Eppendorff tube containing a saturating con-
entration of anti-CD14-PC5 (mouse IgG2a) and anti-
D42a-FITC (mouse IgG1), or their negative monoclonal
ntibodies, and either ADP or TRAP, or an equal volume
f Tyrode’s buffer solution. The reaction was stopped after
15-min period of incubation in static conditions at 37°C.
he fixed samples were kept for a period of 60 min at room
emperature before red cells were lysed by adding a
eckman-Coulter solution at a ratio of 1:10. Dual-color
ow cytometric analyses were then performed within 40 to
0 min, detecting anti-CD14-PC5 at a bandpass filter of
75 nm and anti-CD42a-FITC at 525 nm. Platelets were
tained with anti-CD42a-FITC, and monocytes or neutro-
hils with anti-CD14-PC5. Because monocytes have a
igher expression of CD14 (lipopolysaccharide receptor)
ut a lower granularity compared with neutrophils, they can
eadily be distinguished from neutrophils by a higher mean
uorescence intensity and a lower side scatter for cell
ranularity (Fig. 1). Particles positive to both anti-CD42a-
ITC and anti-CD14-PC5 were identified as platelet-
onocyte or platelet-neutrophil conjugates, depending on
he intensity of anti-CD14-PC and granularities. The
onjugates were assessed as the percentage of the CD42a-
ITC and CD14-PC5–positive particles, reflecting the
ercentage of monocytes/neutrophils with bound platelets,
nd as the mean intensity of CD42a-FITC per particle,
eflecting the number of platelets bound per monocyte-
eutrophil conjugate.
nzyme-linked immunosorbent assay. A tube of fresh
hole blood was centrifuged at 2,200 g (3,500 rpm) for 15
in; the plasma was saved at 70° for subsequent batchnalysis by ELISA of soluble P-selectin (Bender Med
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ystems, Minneapolis, Minnesota), according to the man-
facturer’s instructions.
tatistical analyses. All results are given as the mean value
SD. The data obtained before and after clopidogrel
dministration were compared using paired the Student t
est for within the same patients and by the unpaired t test
or between groups of patients. Potential interactions be-
ween clopidogrel and other cardiovascular drugs were
nalyzed using analysis of variance. The SPSS software
Version 10, SPSS Inc., Chicago, Illinois) was used for all
nalyses. A value p  0.05 was considered statistically
ignificant in all cases.
ESULTS
latelet aggregation and secretion. Platelet counts in
atients were 156 36 109/l before the administration of
lopidogrel and 158  39  109/1 afterward; leukocyte
ounts were also unchanged: 7.1  2.0  109/l and 7.0 
.9  109/l, respectively. When ADP was added ex vivo in
he basal state, it produced 52% platelet aggregation;
RAP, a more potent agonist, induced 77% platelet aggre-
ation. Membrane P-selectin expression was detected in
igure 1. Representative scatter plots of flow cytometric settings for detecti
nd anti-CD42a-FITC. (Left panel) The leukocyte populations are d
anti-CD14-PC5). The cell population with higher CD14-PC5 intensity b
ower CD14 intensity but higher granularity represents neutrophils (ga
D42a-FITC (platelet marker) versus CD14-PC5 (middle and right
nti-CD14-PC5 in region “2” of the scatter plot are identified as platelet-
anel).
Table 1. Platelet Aggregation and P-Selectin E
TRAP (10 mol/l) in Patients With an Acute
Administration of Clopidogrel (n  21)
ADP-Induced Plat
Aggregation
P
E
Pre-drug (%) 51.5  16.5 44
Clopidogrel (%) 28.9  23.3* 29
Inhibition (%) 44%
*p  0.01 vs. pre-drug. †p  0.01 vs. ADP-induced platelet
the same row. Data are expressed as the mean value  SD.ADP  adenosine diphosphate; TRAP  thrombin receptor a5% of platelets with ADP and in 72% with TRAP. The
dministration of clopidogrel in patients with ACS resulted
n a 22.6% absolute reduction (44% of the pre-
dministration level) in the number of aggregating platelets
n response to ADP and in a 21.3% reduction (28% of the
re-administration level) in response to TRAP. The num-
er of platelets expressing P-selectin was reduced by 15.6%
nd 25.1%, respectively (35% of the pre-administration
umber for both ADP and TRAP, p  0.01) (Table 1).
he drug also significantly reduced both soluble CD40L
nd soluble P-selectin in plasma, by 27% and 15%, respec-
ively (p  0.001) (Fig. 2).
latelet-leukocyte conjugates. Figure 1 illustrates a typical
ow cytometric display of platelet-monocyte and platelet-
eutrophil conjugates obtained in one patient with ACS. The
ean results in controls and patients are shown in Figures 3
nd 4. At baseline, before the administration of clopidogrel and
he addition of an agonist in blood, there were significantly
ore platelet-monocyte and platelet-neutrophil conjugates
nd more platelets per conjugate in patients than in controls.
he number of platelet-monocyte conjugates was particularly
igh, exceeding by threefold that of platelet-neutrophil conju-
ates. Adenosine diphosphate intensified the formation of
atelet-monocyte and platelet-neutrophil conjugates using anti-CD14-PC5
uished by their granularities (SS  side scale) and CD14 densities
er granularity represents monocytes (gate B), whereas the population with
Monocytes (gate B) and neutrophils (gate I) are further analyzed by
s, respectively). The particles positive for both anti-CD42a-FITC and
cyte conjugates (middle panel) and platelet-neutrophil conjugates (right
ssion Induced by ADP (10 mol/l) or
onary Syndrome Before and 24 Hours After
TRAP-Induced Platelets
ctin
sion Aggregation
P-Selectin
Expression
15.8 76.9  7.6† 72.2  4.6‡
17.1* 55.6  17.5* 47.1  22.3*
28% 35%
ation. ‡p  0.01 vs. ADP-induced P-selectin expression inng pl
isting
ut low
te I).
panel
monoxpre
Cor
elets
-Sele
xpres
.8 
.2 
35%
aggreggonist peptide.
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June 2, 2004:1982–8 Clopidogrel in Acute Coronary Syndromeshese aggregates and the density of platelets per aggregate.
nce again, monocytes were more active than neutrophils,
ith more than 80% of monocytes and half that amount of
eutrophils, in forming conjugates. Responses to TRAP ex-
eeded those of ADP, although there were no differences
etween ACS patients and controls; more than 90% of
onocytes and more than 70% of neutrophils formed conju-
ates in the two groups. Platelet activity per monocyte was also
wice as intense as the activity per neutrophil.
Clopidogrel completely reverted the number of sponta-
eous conjugates present in the circulation in ACS patients
o control values and further prevented nearly all agonist
ffects of ADP and 50% of the effects of TRAP. The
hanges in the density of platelets per conjugate followed
he same pattern as the changes in the number of conjugates
Figs. 3 and 4).
rug interactions. Potential interactions between the use
f other cardiovascular drugs and the antiplatelet effects of
lopidogrel were explored. Beta-blockers, nitrates, and cal-
ium antagonists had no influence on the amount of
igure 2. Soluble CD40L (n  21; left panel) and soluble P-selectin (n 
nd 24 h after clopidogrel administration.
igure 3. Percentage of monocytes with bound platelets (left panel) and
control no clopidogrel) and in acute coronary syndrome patients before a
10 mol/l) or thrombin receptor agonist peptide (TRAP) (10 mol/l) served asnhibition. The reduction in the density of platelets in
eutrophil conjugates following clopidogrel was of a lesser
agnitude in patients using a statin than in nonusers (14.7
10.3% vs. 26.0  7.2%, p  0.05). The baseline values
ere similar among patients using a statin versus those not
4.3  1.0% vs. 4.6  0.6%); they were also the same in
atients already receiving a statin and in patients in whom
he statin was initiated in the hospital. All other parameters,
owever, including aggregation to ADP and TRAP,
-selectin expression, and the number of platelet-leukocyte
onjugates, were unaffected by the use of a statin.
ISCUSSION
his study provides new insights on the mechanisms, other
han the inhibition of ADP-induced platelet aggregation,
hich could account for some of the benefits of clopidogrel
n patients with an ACS. Importantly, TRAP-induced
latelet activation and aggregation and platelet-leukocyte
nteractions were sensitive to the effects of clopidogrel and
ight panel) plasma levels in patients with acute coronary syndrome before
ber of platelets bound per monocyte (right panel) in normal volunteers
h after a loading dose of clopidogrel. Either adenosine diphosphate (ADP)15; rnum
nd 24the platelet agonist (n 21). *p 0.01 vs. control. p 0.01 vs. pre-drug.
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Clopidogrel in Acute Coronary Syndromes June 2, 2004:1982–8hus were significantly reduced. Clopidogrel also reduced
he presence of spontaneous platelet-monocyte and platelet-
eutrophil conjugates in the circulation, as well as the
lasma levels of P-selectin and CD40L. All these effects are
elieved to be beneficial in patients with ACS and to
ontribute to or be associated with controlling the disease.
latelet aggregation and secretion. Adenosine diphos-
hate is a weak platelet agonist secreted from dense granules
f activated platelets and from damaged vascular tissue and
ed blood cells, whereas TRAP is a strong agonist that acts
n platelets through the protease-activated receptors PAR-1
nd -4. In the study, the two agonists were used at similar
oncentrations. Despite the high specificity of clopidogrel in
locking the ADP P2Y12 platelet receptor and preventing
DP effects (1), the reduction of TRAP-induced platelet
ggregation attained 22%, equaling the absolute amount of
eduction in response to ADP. As a consequence, the level
f aggregation achieved by TRAP with clopidogrel was in
he range of that observed with ADP in the control state.
-selectin expression, a marker of platelet activation, was
imilarly reduced with the two agonists, supporting the
ignificance of the findings on aggregation.
These results are in contrast to those of previous studies
hat have generally reported no or minimal inhibition of
RAP or collagen-induced platelet aggregation with clopi-
ogrel (6,21,22). On the other hand, in line with our
ndings, Klinkhardt et al. (19) reported an inhibition of
RAP-induced P-selectin expression, along with a reduc-
ion in PAC-1 (monoclonal antibody specific for a platelet
ctivation complex near the fibrinogen receptor) expression.
he putative effects of clopidogrel observed in our study on
ifferent pathways to platelet activation are supported by the
revious documentation of an important role of ADP and
he P2Y12 receptors in amplifying and modulating the
ffects of various platelet agonists, including the effects of
hrombin on PAR-1 (23–25). The differences in results
etween studies can likely be explained by the experimental
onditions, study populations, and concomitant drug ther-
py. Patients with ACS enrolled in our study had a high
igure 4. Percentage of neutrophils with bound platelets (left panel) and
control  no clopidogrel) and in acute coronary syndrome patients before a
eceptor agonist peptide (TRAP) (10 mol/l) used as the platelet agonistevel of platelet activation, as witnessed by a hyper- cesponsiveness to the agonist effects of ADP, compared
ith controls, and elevated levels of circulating platelet-
onocyte and platelet-neutrophil conjugates (Figs. 3 and
). The platelet studies were performed 24 h after a loading
ose of 300 mg clopidogrel; this dose produces steady-state
nhibition of platelet aggregation in the range of 40% to
0%. Lower doses require many days before reaching the
ull effect, and higher bolus doses result in the same extent
f inhibition occurring more rapidly (21).
latelet-monocyte and platelet-neutrophil aggregates.
s many as 45% of monocytes and 15% of neutrophils
irculated as heterotypical aggregates in our population of
CS patients. These figures were significantly greater than
hose in control subjects, suggesting a true elevation beyond
hat induced by blood manipulation. Furthermore, these
umbers increased to 85% and 45%, respectively, after
timulation with ADP in ACS patients, again significantly
ore than in controls. With TRAP, the stimulation was
lready maximal in both groups of patients. The formation
f leukocyte-platelet conjugates is mainly mediated by the
inding of P-selectin expressed on activated platelets to
-selectin glycoprotein ligand-1 (PSGL-1) on leukocytes.
ther contributing mechanisms are fibrinogen, which
ross-links activated GP IIb/IIIa receptors on platelets with
ntegrin MAC-1 (CD11b/CD18) on leukocytes, and the
latelet secretion products CD40L and RANTES (Regu-
ated upon Activation; Normal T cell Expressed and Se-
reted) that bind the respective receptors on monocytes and
eutrophils.
The association of platelet-leukocyte interactions with
CS has been well demonstrated in various clinical settings
12–16). The high proportion of platelet-monocyte conju-
ates observed suggests that they may play an important role
n the mechanisms of ACS, although a cause-effect rela-
ionship remains to be documented. Similarly, the presence
f neutrophil conjugates and the platelet hyper-
esponsiveness to agonist stimulation may suggest a more
eneral coronary or systemic inflammatory response. Con-
rol of these aggregates with clopidogrel might therefore
ber of platelets bound per neutrophil (right panel) in normal volunteers
ring clopidogrel, adenosine diphosphate (ADP) (10 mol/l), or thrombin
21). *p  0.01 vs. control. p  0.01 vs. pre-drug.num
nd du
(n ontribute to the benefits of clopidogrel. Other antiplatelet
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June 2, 2004:1982–8 Clopidogrel in Acute Coronary Syndromesrugs have differential effects. Thus, GP IIb/IIIa antago-
ists can increase or decrease the number of platelets per
onjugate and may increase the total number of conjugates
s they activate platelets and promote P-selectin expression
26–28).
Variable effects of clopidogrel have previously been re-
orted. In one study, the drug reduced the ADP agonist
ffects by 50% (18); in another study, it prevented the
ncrease in platelet-monocyte and platelet-neutrophil con-
ugates induced by abciximab (19). These findings, however,
ere not reproduced in 51 patients who were administered
00 mg clopidogrel after successful stent implantation,
ollowed by 75 mg/day; in that study, the number of
latelet-leukocyte aggregates was significantly greater after
4 h, as clopidogrel reached its maximal effect on ADP-
nduced aggregation, whereas PAC-1 binding remained
levated for 30 days (29).
oluble platelet secretion products. Platelet secretion
roducts play important roles in the pathophysiology of
CS, as they mediate numerous interactions between plate-
ets, the coagulation cascade, and the cells involved in
nflammation and atherosclerosis. Their pathophysiologic
ole may differ substantially when expressed on membrane
urfaces functioning by cell interaction or when released in
lood then operating more systematically. Increased blood
evels of soluble CD40L and of P-selectin have been
eported in patients with unstable angina (30). However,
ew studies have looked at the effects of clopidogrel on these
ecretion products. Clopidogrel, but not aspirin, reduced
DP-induced membrane expression of CD40L in one
tudy in normal volunteers (31). In another study, clopi-
ogrel reduced ADP-induced membrane P-selectin expres-
ion but did not influence the soluble form (32). In the
lopidogrel in Unstable angina to prevent Recurrent Events
CURE) trial, long-term administration of clopidogrel had
o effect on soluble P-selectin (33). In our study, both
embrane P-selectin and soluble P-selectin were signifi-
antly reduced within 24 h of the administration of clopi-
ogrel; soluble CD40L levels also decreased.
tudy limitations and conclusions. All patients in our
tudy were treated with unfractionated heparin, which is a
irect pro-aggregant (34) that can also amplify the aggre-
ation induced by other agonists, an effect partly related to
ctivation of the P2Y12 receptor (23). Due to the study
esign, the effects related to heparin are not readily distin-
uished from those related to the disease. Similarly, the
espective effects of clopidogrel and aspirin cannot be
eparated, as all patients received a combination of the two
rugs. Post hoc analyses of data showed no interactions
etween the use of beta-blockers, calcium antagonists, and
itrates and the effects of clopidogrel. A weak interaction
as found with a statin in only one of the multiple tests that
ere done, making a significant influence of statin therapy
n our results unlikely. Although an interaction between
torvastatin and clopidogrel on cytochrome P450 (CYP)
A4 has been reported (35), the significance of this inter-ction remains inconclusive (36). Recent studies have shown
variability in the response to clopidogrel in various platelet
unction tests and suggest that as many as 20% to 30% of
atients could be poor responders (7). A similar variability
as seen in our study in the various tests performed,
ncluding the inhibition of platelet-leukocyte complex for-
ation. Whether this variability in response influences the
linical efficacy of the drug remains to be studied.
Another potential limitation of our study is the absence of
control group of ACS patients randomized to placebo or
o no clopidogrel. Such a group could not be studied because
f ethical issues. It could have influenced the results quan-
itatively but was unlikely to affect the general trends and
onclusions of the study.
Finally, although clopidogrel only partially inhibited the
gonist effects of ADP and TRAP, the inhibition to the two
gonists was of the same magnitude in the clinical setting of
ur study, suggesting that they could both contribute to the
lobal effects of the drug. More complete inhibition of the
latelet purinergic receptors could be expected to magnify
he benefits of pharmacologic inhibition of the ADP recep-
ors. Such approaches are currently available with ATP
nalogues (18,22,37) and with a combination of P2Y1 and
2Y12 blockers (38) and may lead to new perspectives in
ntiplatelet therapy.
eprint requests and correspondence: Dr. Pierre The´roux,
ontreal Heart Institute, 5000 Belanger East, Montreal, Quebec,
anada H1T 1C8. E-mail: pierre.theroux@icm-mhi.org.
EFERENCES
1. Weber AA, Reimann S, Schror K. Specific inhibition of ADP-
induced platelet aggregation by clopidogrel in vitro. Br J Pharmacol
1999;126:415–20.
2. The CAPRIE Steering Committee. A randomised, blinded, trial of
clopidogrel versus aspirin in patients at risk of ischaemic events
(CAPRIE). Lancet 1996;348:1329–39.
3. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK.
Effects of clopidogrel in addition to aspirin in patients with acute
coronary syndromes without ST-segment elevation. N Engl J Med
2001;345:494–502.
4. Bhatt DL, Bertrand ME, Berger PB, et al. Meta-analysis of random-
ized and registry comparisons of ticlopidine with clopidogrel after
stenting. J Am Coll Cardiol 2002;39:9–14.
5. Steinhubl RR, Berger PB, Mann T III, et al., for the CREDO
Investigators. Early and sustained dual oral antiplatelet therapy
following percutaneous coronary intervention. JAMA 2002;288:
2411–20.
6. Payne DA, Hayes PD, Jones CI, Belham P, Naylor AR, Goodall AH.
Combined therapy with clopidogrel and aspirin significantly increases
the bleeding time through a synergistic antiplatelet action. J Vasc Surg
2002;35:1204–9.
7. Gurbel PA, Bliden KP, Hiatt BL, O’Connor CM. Clopidogrel for
coronary stenting: response variability, drug resistance, and the effect of
pretreatment platelet reactivity. Circulation 2003;107:2908–13.
8. Evangelista V, Manarini S, Sideri R, et al. Platelet/polymorphonuclear
leukocyte interaction: P-selectin triggers protein-tyrosine phosphorylation-
dependent CD11b/CD18 adhesion: role of PSGL-1 as a signaling
molecule. Blood 1999;93:876–85.
9. Scholz T, Zhao L, Temmler U, Bath P, Heptinstall S, Losche W. The
GP IIb/IIIa antagonist eptifibatide markedly potentiates platelet-
leukocyte interaction and tissue factor expression following platelet
activation in whole blood in vitro. Platelets 2002;13:401–6.
11
1
1
1
1
1
1
1
1
2
2
2
2
2
2
2
2
2
2
3
3
3
3
3
3
3
3
3
1988 Xiao and The´roux JACC Vol. 43, No. 11, 2004
Clopidogrel in Acute Coronary Syndromes June 2, 2004:1982–80. Henn V, Slupsky JR, Grafe M, et al. CD40 ligand on activated
platelets triggers an inflammatory reaction of endothelial cells. Nature
1998;391:591–4.
1. Lindmark E, Tenno T, Siegbahn A. Role of platelet P-selectin and
CD40 ligand in the induction of monocytic tissue factor expression.
Arterioscler Thromb Vasc Biol 2000;20:2322–8.
2. Ott I, Neumann FJ, Gawaz M, Schmitt M, Schomig A. Increased
neutrophil-platelet adhesion in patients with unstable angina. Circu-
lation 1996;94:1239–46.
3. Sarma J, Laan CA, Alam S, Jha A, Fox KA, Dransfield I. Increased
platelet binding to circulating monocytes in acute coronary syndromes.
Circulation 2002;105:2166–71.
4. Furman MI, Barnard MR, Krueger LA, et al. Circulating monocyte-
platelet aggregates are an early marker of acute myocardial infarction.
J Am Coll Cardiol 2001;38:1002–6.
5. Rinder CS, Bonan JL, Rinder HM, Mathew J, Hines R, Smith BR.
Cardiopulmonary bypass induces leukocyte-platelet adhesion. Blood
1992;79:1201–5.
6. Mickelson JK, Lakkis NM, Villarreal-Levy G, Hughes BJ, Smith
CW. Leukocyte activation with platelet adhesion after coronary
angioplasty: a mechanism for recurrent disease? J Am Coll Cardiol
1996;28:345–53.
7. Schonbeck U, Libby P. CD40 signaling and plaque instability. Circ
Res 2001;89:1092–103.
8. Storey RF, Judge HM, Wilcox RG, Heptinstall S. Inhibition of
ADP-induced P-selectin expression and platelet-leukocyte conjugate
formation by clopidogrel and the P2Y12 receptor antagonist AR-
C69931MX but not aspirin. Thromb Haemost 2002;88:488–94.
9. Klinkhardt U, Graff J, Harder S. Clopidogrel, but not abciximab,
reduces platelet leukocyte conjugates and P-selectin expression in a
human ex vivo in vitro model. Clin Pharmacol Ther 2002;71:176–85.
0. Chew DP, Bhatt DL, Robbins MA, et al. Effect of clopidogrel added
to aspirin before percutaneous coronary intervention on the risk
associated with C-reactive protein. Am J Cardiol 2001;88:672–4.
1. Muller I, Seyfarth M, Rugiger S, et al. Effect of a high loading dose of
clopidogrel on platelet function in patients undergoing coronary stent
placement. Heart 2001;85:92–3.
2. Moshfegh K, Redondo M, Julmy F, et al. Antiplatelet effects of
clopidogrel compared with aspirin after myocardial infarction: en-
hanced inhibitory effects of combination therapy. J Am Coll Cardiol
2000;36:699–705.
3. Storey RF, Sanderson HM, White AE, May JA, Cameron KE,
Heptinstall S. The central role of the P(2T) receptor in amplification
of human platelet activation, aggregation, secretion and procoagulant
activity. Br J Haematol 2000;110:925–34.
4. Trumel C, Payrastre B, Plantavid M, et al. A key role of adeno-
sine diphosphate in the irreversible platelet aggregation induced by
the PAR1-activating peptide through the late activation of
phosphoinositide-3 kinase. Blood 1999;94:4156–65.5. Ravanat C, Leon C, Cazenave JP, Gachet C. Involvement of the
P2cyc but not the P2Y1 ADP receptor in the phosphatidylserine
exposure of activated platelets. Haematologica 2000;85 Suppl:94.
6. Peter K, Schwarz M, Ylanne J, et al. Induction of fibrinogen binding
and platelet aggregation as a potential intrinsic property of various
glycoprotein IIb/IIIa (alphaIIbbeta3) inhibitors. Blood 1998;92:
3240–9.
7. Xiao Z, The´roux P, Frojmovic M. Modulation of platelet-neutrophil
interaction with pharmacological inhibition of fibrinogen binding to
platelet GP IIb/IIIa receptor. Thromb Haemost 1999;81:281–5.
8. Cox D, Smith R, Quinn M, Theroux P, Crean P, Fitzgerald DJ.
Evidence of platelet activation during treatment with a GP IIb/IIIa
antagonist in patients presenting with acute coronary syndromes. J Am
Coll Cardiol 2000;36:1514–9.
9. Gurbel PA, Malinin AI, Callahan KP, Serebruany VL, O’Connor
CM. Effect of loading with clopidogrel on platelet aggregation at the
time of coronary stenting on platelet aggregation and glycoprotein
IIb/IIIa expression and platelet-leukocyte aggregate formation. Am J
Cardiol 2002;90:312–5.
0. Aukrust P, Muller F, Ueland T, et al. Enhanced levels of soluble
and membrane-bound CD40 ligand in patients with unstable
angina: possible reflection of T lymphocyte and platelet involve-
ment in the pathogenesis of acute coronary syndromes. Circulation
1999;100:614 –20.
1. Hermann A, Rauch BH, Braun M, Schror K, Weber AA. Platelet
CD40 ligand (CD40L)-subcellular localization, regulation of expres-
sion, and inhibition by clopidogrel. Platelets 2001;12:74–82.
2. Seyfarth HJ, Koksch M, Roethig G, et al. Effect of 300- and 450-mg
clopidogrel loading doses on membrane and soluble P-selectin in
patients undergoing coronary stent implantation. Am Heart J 2002;
143:118–23.
3. Eikelboom JW, Weitz J I, Budaj A, et al. Clopidogrel does not
suppress blood markers of coagulation activation in aspirin-treated
patients with non–ST-elevation acute coronary syndromes. Eur
Heart J 2002;23:1771–9.
4. Xiao Z, Theroux P. Platelet activation with unfractionated heparin at
therapeutic concentrations and comparisons with a low-molecular-
weight heparin and with a direct thrombin inhibitor. Circulation
1998;97:251–6.
5. Wei C, Lau WC, Waskell LA, et al. Atorvastatin reduces the ability
of clopidogrel to inhibit platelet aggregation: a new drug-drug inter-
action. Circulation 2003;107:32–7.
6. Serebruany VL, Steinhubl SR, Hennekens CH. Are antiplatelet effects
of clopidogrel inhibited by atorvastatin? A research question formu-
lated but not yet adequately tested. Circulation 2003;107:1568–9.
7. Gachet C. ADP receptors of platelets and their inhibition. Thromb
Haemost 2001;86:222–32.
8. Turner NA, Moake JL, McIntire LV. Blockade of adenosine diphos-
phate receptors P2Y(12) and P2Y(1) is required to inhibit platelet
aggregation in whole blood under flow. Blood 2001;98:3340–5.
